Garzaniti N, el Allaf D, D'Orio V, Cremers S, Marcelle R, Carlier J
Acta Cardiol. 1985;40(2):207-15.
We evaluated the hemodynamic effects of the calcium antagonist nifedipine in 13 consecutive patients admitted to the intensive care unit with secondary pulmonary hypertension. Etiology of secondary pulmonary hypertension was: chronic obstructive pulmonary disease (n = 9), pulmonary emboli (n = 2), pulmonary fibrosis (n = 2). We obtained the resting hemodynamic parameters before, and 60, 120, 180 minutes after the sublingual administration of nifedipine 20 mg. All patients had normal pulmonary artery wedge pressure before nifedipine. After 60 minutes, systolic pulmonary artery pressure fell from 72.3 +/- 7 to 57.3 +/- 5.4 mm Hg (p less than 0.005) and mean pulmonary artery pressure from 44.6 +/- 4.0 to 33.6 +/- 3.2 mm Hg (p less than 0.001). Cardiac output rose from 6.36 +/- 0.56 to 7.65 +/- 0.64 l/min (p less than 0.005). The pulmonary vascular resistance fell from 431 +/- 58 to 238 +/- 36 dynes. sec. cm-5 (p less than 0.001). Heart rate, mean systemic arterial pressure, pulmonary artery wedge pressure, total systemic vascular resistance and arterial partial pressure of O2 (PaO2) remained unchanged. In this heterogenous population we were unable to reproduce the results of other authors, showing a correlation between PaO2 and fall of pulmonary vascular resistance. These findings confirm the pulmonary vasodilating effect of nifedipine in patients with secondary pulmonary hypertension.
我们评估了钙拮抗剂硝苯地平对13例因继发性肺动脉高压入住重症监护病房的连续患者的血流动力学影响。继发性肺动脉高压的病因如下:慢性阻塞性肺疾病(9例)、肺栓塞(2例)、肺纤维化(2例)。我们在舌下含服20 mg硝苯地平之前以及之后60、120、180分钟获取静息血流动力学参数。所有患者在服用硝苯地平前肺动脉楔压均正常。60分钟后,收缩期肺动脉压从72.3±7降至57.3±5.4 mmHg(p<0.005),平均肺动脉压从44.6±4.0降至33.6±3.2 mmHg(p<0.001)。心输出量从6.36±0.56升至7.65±0.64 l/min(p<0.005)。肺血管阻力从431±58降至238±36达因·秒·厘米⁻⁵(p<0.001)。心率、平均体循环动脉压、肺动脉楔压、总体循环血管阻力和动脉血氧分压(PaO₂)保持不变。在这个异质性人群中,我们无法重现其他作者的结果,即显示PaO₂与肺血管阻力下降之间存在相关性。这些发现证实了硝苯地平对继发性肺动脉高压患者的肺血管舒张作用。